1. Statistics Korea. Elderly statistics 2018. Statistics Korea; 2018.
3. Koo HJ, Kim MJ, Park H, et al. Prevalence and predictors of polypharmacy among elderly outpatients in a public hospital. Korean J Fam Pract 2020;10:136-142.
4. Jung HW, Kim KI. Multimorbidity in older adults. J Korean Geriatr Soc 2014;18:65-71.
5. Kim JH, Lee SH. Polypharmacy in geriatrics and Beers criteria. Korean J Fam Pract 2020;10:407-417.
6. Park HY, Sohn HS, Kwon JW. Reviews on the current status and appropriate management of polypharmacy in South Korea. Korean J Clin Pharm 2018;28:1-9.
7. Yoon SH, Kim DS, Chae JM, Choi YM, Cho HJ. Establishment of criteria for managing inappropriate polypharmacy in the elderly. Health Insurance Review and Assessment Service; 2022.
8. Jang TY, Kim DW, Park HY, et al. A study on the status of drug prescriptions and underlying diseases and prognosis of polypharmacy users using national health insurance data. National Health Insurance Service Ilsan Hospital; 2019.
11. Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet 2017;389:1778-1780.
12. Anrys P, Boland B, Degryse JM, et al. STOPP/START version 2-development of software applications: easier said than done? Age Ageing 2016;45:589-592.
13. Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing 2017;46:600-607.
16. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021;398:1133-1146.
17. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509-1524.
18. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-2473.
20. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
22. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol 2014;114:401-406.
23. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.